<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04723940</url>
  </required_header>
  <id_info>
    <org_study_id>JPAR 20D.1085</org_study_id>
    <nct_id>NCT04723940</nct_id>
  </id_info>
  <brief_title>Or v IV Antibiotics for Infection</brief_title>
  <official_title>Oral vs Intravenous Antibiotics for Treatment of Periprosthetic Joint Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rothman Institute Orthopaedics</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rothman Institute Orthopaedics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Management of periprosthetic joint infection (PJI) commonly includes 6 weeks of intravenous&#xD;
      (IV) antibiotics after surgical treatment. However, there is little evidence to suggest that&#xD;
      oral (PO) therapy results in worse outcomes. This study aims to determine whether or not PO&#xD;
      antibiotics are non-inferior to IV antibiotics in treating PJI. The study is a multicenter,&#xD;
      parallel-group, randomized (1 : 1), open-label, non-inferiority trial. The non-inferiority&#xD;
      margin will be set at 10%. Adults with a clinical diagnosis of PJI according to the&#xD;
      International Consensus Meeting (ICM) criteria who would ordinarily receive at least 6 weeks&#xD;
      of antibiotics and have received ≤ 7 days of IV therapy from surgery will be included. A&#xD;
      total of 308 participants will be centrally computer-randomized to PO or IV antibiotics to&#xD;
      complete the first 6 weeks of therapy. Follow-on PO therapy will be permitted in either arm.&#xD;
      The primary outcome is the proportion of participants experiencing treatment failure within 1&#xD;
      year. An associated cost-effectiveness evaluation including complications, resource&#xD;
      utilization and quality-of-life data will be performed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">January 25, 2021</start_date>
  <completion_date type="Anticipated">January 25, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 25, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Postoperative Infections</measure>
    <time_frame>2 years</time_frame>
    <description>The investigator will measure the incidence of postoperative infections in participants treated with oral antibiotics versus those treated with intravenous antibiotics</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">308</enrollment>
  <condition>Joint Infection</condition>
  <arm_group>
    <arm_group_label>Oral Antibiotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participant will receive 6 weeks of oral antibiotic therapy to treat their infection. The type of antibiotic given will be at the discretion of the infectious disease doctor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous Antibiotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participant will receive 6 weeks of intravenous (IV) antibiotic therapy to treat their infection. The type of antibiotic given will be at the discretion of the infectious disease doctor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bactrim</intervention_name>
    <description>Bactrim will be given for 6 weeks to treat joint infection</description>
    <arm_group_label>Intravenous Antibiotics</arm_group_label>
    <arm_group_label>Oral Antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefadroxil</intervention_name>
    <description>Cefadroxil will be given for 6 weeks to treat joint infection</description>
    <arm_group_label>Intravenous Antibiotics</arm_group_label>
    <arm_group_label>Oral Antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline Hcl</intervention_name>
    <description>Doxycycline HCl will given for 6 weeks to treat joint infection</description>
    <arm_group_label>Intravenous Antibiotics</arm_group_label>
    <arm_group_label>Oral Antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin</intervention_name>
    <description>Clindamycin will given for 6 weeks to treat joint infection</description>
    <arm_group_label>Intravenous Antibiotics</arm_group_label>
    <arm_group_label>Oral Antibiotics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  aged ≥ 18 years&#xD;
&#xD;
          -  willing and able to give informed consent&#xD;
&#xD;
          -  primary THA or TKA diagnosed with PJI based on International Consensus Meeting&#xD;
             criteria&#xD;
&#xD;
               1. A sinus communicating with the prosthesis OR&#xD;
&#xD;
               2. Two positive cultures obtained from the prosthesis OR&#xD;
&#xD;
               3. 3 of 5 criteria:&#xD;
&#xD;
          -  Elevated ESR (&gt;30mm/hr) and CRP (&gt;10mg/L)&#xD;
&#xD;
          -  Elevated synovial leukocyte count (&gt;3000 cells/µL) or change of ++ on leukocyte&#xD;
             esterase strip&#xD;
&#xD;
          -  Elevated synovial neutrophil percentage (&gt;80%)&#xD;
&#xD;
          -  One positive culture&#xD;
&#xD;
          -  Positive histological analysis of periprosthetic tissue (&gt;5 neutrophils per high power&#xD;
             field in 5 high power fields x400)&#xD;
&#xD;
          -  PJI treated by debridement and implant retention, or excision of the prosthetic joint&#xD;
             (with or without planned reimplantation)&#xD;
&#xD;
          -  received ≤ 7 days of IV therapy after an appropriate surgical intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously treated for native septic arthritis or PJI in the same joint&#xD;
&#xD;
          -  S. aureus bacteremia on presentation or within the previous month&#xD;
&#xD;
          -  clinical, histological or microbiological evidence of mycobacterial, fungal or&#xD;
             parasitic etiology of the infection&#xD;
&#xD;
          -  any other concomitant infection that, in the opinion of the clinician responsible for&#xD;
             the patient, requires a prolonged course of IV antibiotic therapy (e.g. bacterial&#xD;
             endocarditis, mediastinal infection, central nervous system infection)&#xD;
&#xD;
          -  septic shock or systemic features that, in the opinion of the clinician responsible&#xD;
             for the patient, requires a course of IV antibiotic therapy (the patient could be&#xD;
             re-evaluated if these features resolved)&#xD;
&#xD;
          -  an infection for which there are no suitable antibiotic choices to permit&#xD;
             randomization between the two arms of the trial (e.g. when organisms are only&#xD;
             sensitive to IV antibiotics or PO antibiotics)&#xD;
&#xD;
          -  unlikely to comply with trial requirements following randomization in the opinion of&#xD;
             the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rothman Orthopaedic Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 22, 2021</study_first_submitted>
  <study_first_submitted_qc>January 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>January 22, 2021</last_update_submitted>
  <last_update_submitted_qc>January 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Cefadroxil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

